Cargando…
Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant from benign Breast Tumors
BACKGROUND: The lack of sensitivity and specificity of existing diagnostic markers like Carbohydrate Antigen 15-3(CA15-3) and Carcinoembryonic antigen (CEA) in breast cancer stimulates the search for new biomarkers to improve diagnostic sensitivity especially in differentiating benign and malignant...
Autores principales: | Baba, K S S Sai, Abdul Rehman, Mohd, Kumar, J Pradeep, Fatima, Maira, Raju, G S N, Uppin, Shantveer G, Mohammed, Noorjahan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8629466/ https://www.ncbi.nlm.nih.gov/pubmed/34452565 http://dx.doi.org/10.31557/APJCP.2021.22.8.2509 |
Ejemplares similares
-
Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors
por: Fatima, Maira, et al.
Publicado: (2022) -
Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses
por: Dewan, Rupali, et al.
Publicado: (2019) -
Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women
por: Tian, Yaping, et al.
Publicado: (2015) -
Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors
por: Gasiorowska, Emilia, et al.
Publicado: (2019) -
Human Epididymis Protein-4 (HE-4): A Novel Cross-Class Protease Inhibitor
por: Chhikara, Nirmal, et al.
Publicado: (2012)